Current status and future prospects of antibody–drug conjugates in urological malignancies-Reference-Cited by-同舟云学术

Current status and future prospects of antibody–drug conjugates in urological malignancies

Published:2022-05-17 Issue:10 Volume:29 Page:1100-1108
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Hayashi Tetsutaro¹,Hinata Nobuyuki¹^ORCID

Affiliation:

1. Department of Urology Hiroshima University Graduate School of Biomedical and Health Science Hiroshima Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14925

Reference57 articles.

1. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

2. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer

3. Phase‐I clinical comparative‐study of monoclonal‐antibody Ks1/4 and Ks1/4‐methotrexate immunoconjugate in patients with non‐small‐cell lung‐carcinoma;Elias DJ;Cancer Res.,1990

4. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

5. Targeting CD30 in Anaplastic Large Cell Lymphoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-08-20

2. A New Age of Drug Delivery: A Comparative Perspective of Ferritin–Drug Conjugates (FDCs) and Antibody–Drug Conjugates (ADCs);Bioconjugate Chemistry;2024-08-12

3. Novel Targeted Therapies for Renal Cell Carcinoma;Hematology/Oncology Clinics of North America;2023-10

4. Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives;Journal of Personalized Medicine;2023-08-30

5. Expression of Nectin-4 in Variant Histologies of Bladder Cancer and Its Prognostic Value—Need for Biomarker Testing in High-Risk Patients?;Cancers;2022-09-11